Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Gross Profit (2016 - 2023)

Perspective Therapeutics (CATX) has disclosed Gross Profit for 14 consecutive years, with -$39000.0 as the latest value for Q4 2023.

  • Quarterly Gross Profit changed N/A to -$39000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2023, down 48.44% year-over-year, with the annual reading at $1.4 million for FY2023, N/A changed from the prior year.
  • Gross Profit hit -$39000.0 in Q4 2023 for Perspective Therapeutics, down from $738000.0 in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $1.7 million in Q1 2020 to a low of -$39000.0 in Q4 2023.
  • Historically, Gross Profit has averaged $971947.4 across 5 years, with a median of $1.1 million in 2020.
  • Biggest five-year swings in Gross Profit: soared 135.88% in 2019 and later crashed 73.22% in 2023.
  • Year by year, Gross Profit stood at $1.1 million in 2019, then increased by 5.04% to $1.2 million in 2020, then rose by 4.54% to $1.2 million in 2021, then crashed by 66.07% to $414000.0 in 2022, then plummeted by 109.42% to -$39000.0 in 2023.
  • Business Quant data shows Gross Profit for CATX at -$39000.0 in Q4 2023, $738000.0 in Q3 2023, and $248000.0 in Q2 2023.